Men with benign prostatic hyperplasia (BPH) will soon have a therapeutic option that uses a unique drug delivery system. The FDA recently approved alfuzosin (UroXatral, Sanofi-Synthelabo) extended-release tablets for the treatment of the signs and symptoms of BPH. Alfuzosin is not indicated for the treatment of hypertension. The manufacturer expects alfuzosin to be available in pharmacies sometime in the second half of 2003.
Patient Outcomes, Holistic Care Hinges on Evolving Role of Pharmacist | Asembia 2025
Published: April 29th 2025 | Updated: April 29th 2025From medication dispensers to comprehensive patient care advocates, pharmacists have never been more essential to the health care team and to patients in specialty care.